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ABSTRACT 
The prevalence of herpes simplex virus (HSV) infection globally is high, and although 
there is no cure for it, the antiviral drug acyclovir is used to alleviate symptoms. There 
are two types of HSV: HSV-1, which typically infects the oral area, and HSV-2, which is 
associated with genital infections. A mother who carries the infection may transmit it to a 
neonate in different ways, most commonly via vaginal delivery in the presence of active 
lesions. There are three types of HSV disease that affect newborns: skin, eyes or mouth 
(SEM) disease, central nervous system (CNS) disease, or disseminated disease. The 
purpose of this study was to examine the long-term effects of the infection and the 
treatment used in neonates infected with HSV. Data collection consisted of original case 
reports published in Medline, CINHAL, and Google Scholar. Two case reports were 
found, and this narrative review compares the cases, which report recurrences and 
outcomes of HSV infection identified in the three databases. Both cases were consistent 
with recurrence of CNS disease, and one showed signs of a slight developmental delay 
that may have been related to the CNS insult.  
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Herpes simplex viruses type 1 and 2 (HSV-1 and HSV-2) are double-stranded, 
DNA viruses commonly transmitted sexually leading to infections that can affect the 
oral (HSV-1) or genital (HSV-2) areas. Although no cure has been found yet, the 
infection can be treated with the antiviral drug acyclovir. The treatment of a first 
outbreak in adults consists of 400 mg of acyclovir orally, three times a day for seven to 
ten days (Whitley, 2007). For adults with recurrent outbreaks, meaning that they have 
had an initial treatment, the drug dose is 400 mg taken orally twice a day for seven 
days. This is important to know because it is the treatment that a mother who has been 
infected would receive to minimize the duration of outbreaks and to prevent recurrent 
viral shedding. It is recognizable when an expectant mother has an outbreak because 
lesions appear in the infected areas. A typical lesion is an ampulla or blister that may 
bleed or ooze a limited amount of fluid, and the outbreak area may present with pruritus 
or a burning sensation. 
Adults infected with HSV, regardless if it is type 1 or 2, may transmit the virus to 
a newborn in three different ways. First, it may be transmitted during birth through the 
vaginal canal with an active outbreak. Second, the neonate may be exposed to HSV 
when the amniotic sac ruptures. Third, a caregiver with an active infection may transmit 
it to the newborn. A baby born to a mother with a first-time lesion has 25% to 60% risk 
of infection, whereas a baby born to a mother who has a recurring infection is less likely 
to be infected (i.e., 2% rate) (Harris & Holmes, 2017). It has been recommended that 
pregnant women who are aware of their infection, even if they do not have lesions at 
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the time, start acyclovir therapy at 36 weeks of gestation (Harris & Holmes, 2017). This 
therapeutic approach does not prevent virus transmission, rather, it decreases the 
number of outbreaks that the mother may have when getting closer to labor and birth. 
If the newborn is infected with HSV during birth, they may present the first signs 
and symptoms between the moment of birth up to two months after. Some of the 
symptoms, such as fever and infection, may resemble other conditions and may be 
misdiagnosed as a bacterial infection. Assuming that both the provider and mother are 
aware of the mother’s existing infection, the first step after the baby is born is to test the 
newborn for HSV within 24 hours of birth (Harris & Holmes, 2017). Nevertheless, there 
are cases were the mother is unaware of her infection because it has been dormant 
until labor. If this is the case and the neonate show signs of infection, they must be 
tested for HSV as well. 
A neonatal HSV infection may manifest in three ways. First, when the infection 
involves the skin, eyes, and mouth (SEM), it usually manifests around the fifth to 
eleventh day of life, with lesions around the mouth and the skin, without involvement of 
the central nervous system (CNS) or the internal organs. Just like in adults, the therapy 
of preference to treat this virus is acyclovir, nevertheless the route of administration and 
the strength of the dosage is different. For neonates, the treatment of HSV is 
intravenous acyclovir 60 mg/kg/day every 8 hours, three times a day, for 14 days 
(Pinninti et al, 2018). If the SEM disease is not treated in time or if it is mistreated or 
mistaken for a bacterial infection, it may progress and develop into CNS or 
disseminated disease. Health care providers try to avoid this progression because out 
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of the three types of disease, SEM disease is the least dangerous and aggressive 
(Harris & Holmes, 2017). 
A second form of the disease is the CNS disease, which generally manifests 
around the eighth to seventeenth day of life. Before manifestation of this form of the 
disease, the neonate is most likely asymptomatic, unless the disease arises from an 
untreated SEM disease, or the mother was unaware that she is a carrier of the HSV 
virus, so the baby was not tested during their first 24 hours of life. Symptoms mirror 
neonatal bacterial infections, therefore a test on the cerebrospinal fluid (CSF) must be 
conducted to verify if the neonate has indeed a bacterial or a viral infection. According 
to Harris and Holmes, “a total of 50% of neonates who are diagnosed with a localized 
CNS disease will die, and the ones [who] survive will have severe neurologic sequelae” 
(2017, p. 89). Just like in the SEM disease, the treatment for the CNS disease is 
acyclovir 60 mg/kg/day three times a day, but in this case, therapy duration is 21 days. 
Last, neonatal HSV infection may manifest as disseminated disease, which 
involves various internal organs, such as the lungs, liver, CNS, and/or adrenal glands 
(Pinninti et al, 2018). Typically, neonates with disseminated disease appear with fever, 
renal and/or lung failure, and may experience disseminated intravascular coagulopathy 
(Harris & Holmes, 2017). It has been shown that “nearly 30% of newborns with 
disseminated disease die even with treatment” (Harris & Holmes, 2017, p.89). As with 
the previous forms of neonatal HSV disease, newborns who have been infected are 
treated with intravenous acyclovir 60 mg/kg/day every 8 hours for 21 days. 
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Herpes simplex virus infection may be asymptomatic for years or may manifest 
with symptoms immediately after the infection. If a pregnant woman knows that she has 
an HSV-2 infection or if her healthcare professional suspects the infection, the newborn 
must be tested for HSV within 24 hours after birth. If the neonate tests positive, they 
must be treated in a timely manner. Some studies “recommend giving oral acyclovir 
therapy at a dose of 300 mg three times a day for six months after completion of 
[intravenous] therapy” (Bhatta et al., 2018, p. 690). Nevertheless, it has been shown 
that long-term use of acyclovir can lead to neutropenia, which can lead to increased 
vulnerability to other infections. Neutropenia may be self-limited following treatment 
with acyclovir but monitoring of neutrophil count is still recommended during treatment 
(Whitley, 2007). 
After reviewing the different types of neonatal syndromes associated with HSV 
infection and understanding the treatment for infected adults and neonates, it is evident 
that there is a gap in the literature for the long-term effects of both the neonatal HSV 
infection and its therapy. Thus, this study aims to describe the long-term effects 






 A narrative literature review was the design of choice for this study to critically 
review the literature on neonatal HSV infection and its long-term outcomes. In this 
study, congenital herpes infection was defined as a newborn who showed the presence 
of the virus between the fifth and seventeenth days of life. This study focused on finding 
the effects of the HSV infection in patients who were initially diagnosed within their first 
month of life.  
Data sources and search strategy 
Data search was conducted among original publications in English without 
date limits in PubMed, the Cumulative Index to Nursing and Allied Health Literature 
(CINAHL), and Google Scholar. Table 1 showcases the keywords and phrases 
related to HSV that were used to conduct multiple searches. 
Table 1. Keywords used for data search 
Search on PubMed and CINAHL  Search on Google Scholar 
Neonatal and HSV and effects Adult survivors of herpes at birth  
Herpes simplex virus and neonatal and long-
term effects 
Antiviral therapy for HSV 
Herpes simplex virus and mother-to-child 
transmission 
Neonatal viral simplex infection and acyclovir 
HSV and neonatal prognosis or outcome Incidence of congenital hsv infection 
Congenital herpes and treatment or 




Articles were selected if they contained original reports of long-term outcomes of 
neonatal HSV infection or therapy. Articles that did not report original data or that did 
not discuss the long-term outcomes of the infection or therapy were discarded. 
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Data extraction 
Articles meeting the inclusion criteria were retrieved and read in full by the author. 
After reviewing the reports, key demographic variables on the cases were extracted in a 
matrix, namely: age, gender, time of initial HSV infection, HSV type, course of treatment 




 The purpose of this study was to investigate the long-term side effects of 
neonatal HSV infection and treatment. The search in all three databases identified four 
records matching the keyword search, published between 2009 and 2017. Two 
publications were excluded: one was a commentary on the dearth of studies on the 
long-term outcomes of neonatal HSV infection (Melvin et al., 2015) and one was a 
review on the treatment of neonatal HSV infection, without reporting long-term 
outcomes (Jones et al., 2009). Thus, two studies reporting original data remained in this 
analysis (Henderson et al., 2015; Kato et al., 2017). Table 2 presents the key findings 
extracted from these reports, followed by a summary of each case. 
Table 2. Summary of the characteristics of the case reports reviewed. 
Study Kato et al., 2015 Henderson et al., 2017 
Country Japan Not specified 
Sex Boy  Girl 
Age at initial infection 12 days old 10 days old 
Treatment at initial infection Intravenous acyclovir 20 
mg/kg every 8h for 21 days 
Intravenous acyclovir 60 mg/kg per 
day for 21 days  
Type of virus and disease HSV-2 with CNS disease HSV-2 with CNS disease 
Age at recurrence 7 months old 7 years old 
Treatment at recurrence Intravenous acyclovir 15 
mg/kg every 8h for 21 days 
Intravenous acyclovir for 21 days 
Long-term outcomes reported Delayed in development Not specified  
 
Case report 1 (Kato et al., 2015) 
 A 12-day-old boy was vaginally delivered by a mother with previous history of 
HSV-1, without history of HSV-2. For his first 11 days of life, he showed no signs or 
symptoms of an infection (no fever, lesions, vomiting, etc.) All laboratory results for the 
boy were within range. Nevertheless, a magnetic resonance imaging (MRI) showed 
brain hemorrhage. After a spinal tap, the baby was diagnosed with neonatal HSV 
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infection with CNS disease. The treatment prescribed was intravenous acyclovir 
20 mg/kg per dose every eight hours for 21 days. After completing the intravenous 
treatment, the blood and CSF laboratory results came back negative for HSV infection 
and the patient was prescribed oral valacyclovir for six months. 
 Nevertheless, he was brought back to the hospital with fever 14 days after 
completing the oral therapy. A spinal tap showed presence of HSV in the cerebrospinal 
fluid (CSF), so he was started once more on intravenous acyclovir for 21 days. 
Following this, he was administered oral therapy for a year. When the second oral 
suppressive therapy ended, a standardized developmental test showed slight delay in 
his development. No recurrences were reported proceeding the last round of oral 
therapy, this after being followed up for a year.  
Case report 2 (Henderson et al, 2017) 
 A 7-year-old girl presented with headaches, dizziness, and signs of vomiting. She 
had a history of neonatal HSV-2 infection with CNS disease at 10 days of age. After the 
diagnosis, she received intravenous acyclovir for 21 days, and after this, she followed 
an oral therapy of acyclovir for six months. The patient did not show any symptoms of 
HSV infection until seven years later. 
 During the recurrent episode, all laboratory results for HSV infection were within 
range, except for the CSF test, which was positive for HSV-2. This confirmed a 
diagnosis of HSV-2 meningitis. She received intravenous acyclovir for 21 days, 
resolving her symptoms by the third day on treatment. After completing the treatment, 
laboratory results were negative for HSV-2 infection, and she was discharged with oral 
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 The aim of this narrative review was to describe reports on the long-term 
outcomes of neonatal HSV treated with acyclovir. Only two case reports met the 
inclusion criteria and were included. Both cases reported recurrence of HSV in patients 
previously diagnosed and treated for HSV with CNS involvement during the neonatal 
period. Neither case ever showed signs of skin lesions or rashes suggesting that the 
CNS disease did not progress from SEM disease. Treatment was the same for both 
cases when they were first diagnosed (i.e., intravenous acyclovir for 21 days), followed 
by antiviral suppressive therapy of oral valacyclovir or acyclovir for six months. 
One of the differences between the two case reports was the time between the 
recurrences. While the male patient had a recurrence approximately seven months after 
the initial insult, the female patient experienced an interval of seven years between 
outbreaks. One potential reason for this difference is that the male patient was treated 
with oral valacyclovir as the suppressive therapy, and the female patient was prescribed 
acyclovir for the same purpose. Nevertheless, both case reports explain that a 
shortened course of therapy can be a big factor in the sequelae of the disease, 
explaining why after the intravenous therapy, there’s an oral suppressive therapy for a 
longer period. 
Another of the differences found was the age of recurrence. The boy had a CNS 
recurrence at 7 days of age, whereas the girl had a CNS recurrence at age 7. Time to 
recurrence has long been reported as highly unpredictable (Corey, 1988), which is 
consistent with the disparity in the age of recurrence in the two cases at hand. 
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Finding only two cases greatly limits the extrapolation and analyses of long-term 
outcomes after an initial neonatal HSV infection. Several reasons might be behind this 
phenomenon, including efficacy of acyclovir treatment, changes in HSV disease 
prevalence, and the role of stigma in disclosing and treating sexually transmitted 
infections. These potential reasons for a dearth in the long-term outcomes reported are 
discussed next. 
Efficacy of the treatment 
 For the initial treatment of both HSV-1 and HSV-2 in neonates, intravenous 
administration of the antiviral drug acyclovir is prescribed. This drug has been available 
for medical use for over three decades and it has showed outstanding efficacy for 
treating an initial viral infection in neonates, as it not only reduces the days with active 
infection, but also lowers the odds of recurrence and mortality among newborns 
(Kimberlin & Whitley, 2007). Previously, HSV infection was treated with vidarabine, and 
although both vidarabine and acyclovir were effective, vidarabine required high doses, 
making acyclovir the treatment of choice, not only because it requires a lower dose, but 
it is also easier to administer. Despite its ability to improve symptoms and reduce the 
days of active infection, acyclovir is not a cure  
 In the first case report (Kato et al., 2015), the boy was treated with valaciclovir, a 
prodrug of acyclovir, as the oral suppressive therapy after the first intravenous treatment 
with acyclovir. A study showed that both acyclovir and valaciclovir have the same 
effects when used as oral suppressive therapy (Miserocchi et al., 2007); however, 
Gupta et al. (2004) report that valacyclovir is better absorbed. Nevertheless, considering 
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the results of the two case reports in which valacyclovir was used for the suppressive 
therapy post initial outbreak in the male patient and acyclovir was used as suppressive 
therapy for the female patient, one might speculate acyclovir is more effective for this 
purpose because the female patient did not have a recurrence for seven years, while 
the male patient treated with valacyclovir, had a second outbreak two weeks after the 
termination of the initial suppressive oral therapy. This is merely speculation as a 
conclusion cannot be drawn based on two case studies. A well-powered, long-term 
randomized controlled clinical trial comparing the use of acyclovir versus valacyclovir 
would be needed to make this conclusion. 
 It is important to point out that, before acyclovir was discovered to work against 
the HSV infection, a great percentage of patients with congenital herpes died within their 
first year of life. Based on the effectiveness of acyclovir in treating an initial HSV 
infection in neonates, one might infer that there may be a long-term benefit of this drug 
in terms of decreasing the chance of having an outbreak later in life, as was the case in 
the female case report. Nevertheless, this too is speculation and would need to be 
borne out by a long-term clinical trial. 
Change in HSV incidence rate 
 Before acyclovir treatment was commonplace, for every five pregnant women not 
infected with HSV-2 there was one pregnant woman with the infection (Whitley et al, 
2007). Even though the neonate may acquire the infection from someone with either 
genital or oral herpes, the most common mechanism reported is vaginal delivery 
occurring when an active outbreak is present in the mother (James & Kimberlin, 2015). 
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It is important to point out that, according to the National Center for Health Statistics 
(NCHS), from 2000 (18.0%) to 2016 (12.1%), the incidence of HSV-2 infection in ages 
14-49 has decreased by almost 6% (McQuillan et al., 2018). Whereas the incidence of 
HSV-1 infection among the same age group and time interval decreased by about 11%, 
going from 59.4% to 48.1% (McQuillan et al., 2018). The declining incidence may be the 
result of education about the importance of using protection during sexual activity and 
knowing the medical history of the sexual partners to avert sexually transmitted 
infections. 
The role of stigma 
 It is not a secret that sexually transmitted infections (STIs) are stigmatized 
worldwide resulting in patients being marginalized and shamed for their sexual history. 
Researchers believe that, due to potential shame, parents may be reluctant to speak out 
about their STIs and how they transmitted it to their babies (Melvin et al., 2015). It is 
possible that mothers omit informing their child about their past medical history due to 
the possible guilt they may feel. Expectant mothers with HSV infections may fail to tell 
their healthcare provider about their own medical record, again, for the possible shame 
they may feel. Because of this, it is presumed that parents would not enroll their children 
in studies that aim to research the long-term outcomes of this infection in neonates. 
The aforementioned implications of efficacy and stigma may explain, at least 
partially, why there are not enough follow-up studies on children after the initial 
diagnosis of neonatal HSV. 
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Possible transmission to future sexual partners 
 Viral infections like HSV do not have a cure as the virus continues to reside in the 
body. Even though babies get treated after initial diagnosis, it is known that the virus 
stays latent in the dorsal ganglia of the spinal cord, and it has the potential to recur at 
any time. HSV infection may remain dormant for many years and may never show signs 
or symptoms of infection in the future. Whether HSV infection acquired as a neonate 
can be transmitted to a future sexual partner is unknown, so researchers cannot confirm 
or eradicate the question of possible partner-to-partner transmission of neonatally 
acquired HSV infection. 
Study limitations 
 There are several limitations of the investigation undertaken to explore the long-
term effects of neonatal HSV infection and treatment. The dearth of research and case 
reports in the literature presented the greatest limitation to answer the research 
questions, with only two case reports identified from the databases used for this 
research. The lack of reports may be due in part to reporting and subject bias. Narrative 
reviews like this one depend on previous publications, but there is a possibility that 
clinicians are not reporting recurrences of neonatal herpes infections. This may be due 
to their busy schedules or their lack of knowledge about the current gap in the literature 
on long-term outcomes of neonatal HSV infection. It is also possible that asymptomatic 




 The signs and symptoms of neonatally acquired HSV infection are treatable with 
antiviral therapy; however, recurrence of symptoms, as has been documented in two 
published case reports, is possible, with the length of time between the initial and 
subsequent outbreaks varying between the two cases. Triggers that may cause 
recurrence are yet to be identified, as is the true frequency with which subsequent 
outbreaks occur. Based on the documented cases identified for this project, one 
difference that may account for variability in the length of time from the initial to 
subsequent outbreak might be related to the choice of drug therapy; however, there is 
purely speculation that needs to be borne out through additional research. Even though 
there is not much literature on the inquiry of this project, the fact that long-term sequelae 
were documented in the two case reports where CNS disease recurred, suggests the 
need for surveillance, reporting, research, and strategies for prevention. Future studies 
might include an observational study that systematically reviews and compares all 
cases of neonates acquiring HSV infection during the perinatal period through 
adolescence or adulthood. Although this type of study could provide data needed to 
support the need for further investigation using a more rigorous study design, a 
drawback to this approach would be the duration of time needed to identify possible 
patterns or associations. Given enough evidence to support the idea that differences in 
therapeutic approaches might be related to the duration between initial and subsequent 
occurrence, a randomized clinical trial comparing treatment approaches would be in 
order and would provide more concrete evidence to support or refute this hypothesis.  
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